Evidence mapPaperPMID 42473560Full record

ReviewInternational journal of nanomedicine2026

Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.

Xin Li, Fei Teng

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xin LiDepartment of Radiology, The Second Hospital of Jilin University, Changchun, 130000, People's Republic of China.
Fei TengDepartment of Radiology, The Second Hospital of Jilin University, Changchun, 130000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metal-organic frameworks (MOFs) are an emerging class of porous nanomaterials for tumor imaging owing to their tunable porosity, exceptionally high surface area, confinement effect, and high density of active sites, which collectively enable superior loading efficiency, signal amplification, and multifunctionality compared with conventional nanoplatforms. This review is a general overview of the advances that have been conducted in the development of imaging agents based on MOFs, with the perspective of their use in different imaging modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET), fluorescence imaging, and computed tomography (CT). All the peculiarities of MOFs, including the possibility to introduce a metal, adjust the surface, and combine different imaging methods into one are described in detail. We also discuss the application of MOFs to tumor targeting and drug delivery and how this system can be functionalized to allow targeting of tumors and the possibility of personalized therapy. Despite these advantages, major barriers including complex synthesis, limited physiological stability, potential toxicity, scalability issues, and regulatory constraints continue to widen the bench-to-bedside gap and hinder the clinical translation of MOF-based imaging systems. New technologies in the design of MOFs, including hybrid and multifunctional MOFs, present new possibilities to improve imaging sensitivity, resolution, and therapeutic success. Future perspectives including theranostic integration and potential clinical applications of MOF-based imaging platforms are also discussed. Finally, despite the presence of multiple challenges, MOFs can be used to revolutionize the field of tumor imaging and enhance the process of cancer diagnosis and treatment with more sensitive, targeted, and personalized strategies.

Indexed as

Diagnostic ImagingNeoplasmsOrganometallic CompoundsAnimalsContrast MediaHumansContrast MediaOrganometallic Compoundsdrug deliverymetal-organic frameworksmultimodal imagingpersonalized medicinetumor imaging

Identifiers

PMID42473560
PMCPMC13380907

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.